ID27019A - Tablet farmasi salutan usus dan metode pembuatan - Google Patents

Tablet farmasi salutan usus dan metode pembuatan

Info

Publication number
ID27019A
ID27019A IDW20010105A ID20010105A ID27019A ID 27019 A ID27019 A ID 27019A ID W20010105 A IDW20010105 A ID W20010105A ID 20010105 A ID20010105 A ID 20010105A ID 27019 A ID27019 A ID 27019A
Authority
ID
Indonesia
Prior art keywords
tablets
making
methods
pharmaceutical sales
sales
Prior art date
Application number
IDW20010105A
Other languages
English (en)
Inventor
Ismat Ullah
Gary J Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ID27019A publication Critical patent/ID27019A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20010105A 1998-07-17 1998-08-06 Tablet farmasi salutan usus dan metode pembuatan ID27019A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11841898A 1998-07-17 1998-07-17

Publications (1)

Publication Number Publication Date
ID27019A true ID27019A (id) 2001-02-22

Family

ID=22378467

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010105A ID27019A (id) 1998-07-17 1998-08-06 Tablet farmasi salutan usus dan metode pembuatan

Country Status (35)

Country Link
US (2) US6331316B1 (id)
EP (1) EP1098635B1 (id)
JP (1) JP2002520350A (id)
KR (1) KR100535954B1 (id)
CN (1) CN1195499C (id)
AR (1) AR019934A1 (id)
AT (1) ATE268165T1 (id)
AU (1) AU750388B2 (id)
BG (1) BG65443B1 (id)
BR (1) BR9815948A (id)
CA (1) CA2337885C (id)
CO (1) CO5090840A1 (id)
CZ (1) CZ301557B6 (id)
DE (1) DE69824319T2 (id)
DK (1) DK1098635T3 (id)
EE (1) EE05021B1 (id)
EG (1) EG23944A (id)
ES (1) ES2221188T3 (id)
GE (1) GEP20032912B (id)
HU (1) HU226492B1 (id)
ID (1) ID27019A (id)
IL (1) IL139701A0 (id)
LT (1) LT4844B (id)
LV (1) LV12638B (id)
NO (1) NO330554B1 (id)
NZ (1) NZ508298A (id)
PL (1) PL195587B1 (id)
PT (1) PT1098635E (id)
RO (1) RO121082B1 (id)
RU (1) RU2201217C2 (id)
SK (1) SK285152B6 (id)
TR (1) TR200003577T2 (id)
UA (1) UA73092C2 (id)
WO (1) WO2000003696A1 (id)
ZA (1) ZA993446B (id)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6756811B2 (en) * 2000-03-10 2004-06-29 Easic Corporation Customizable and programmable cell array
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
CA2438641A1 (en) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
GB2379854B (en) * 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CA2461870A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
US20030181524A1 (en) * 2001-10-29 2003-09-25 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
AU2003201735B2 (en) * 2002-01-11 2008-11-13 Circ Pharma Research And Development Limited Pravastatin pharmaceutical formulations and methods of their use
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
WO2003072089A1 (en) * 2002-02-21 2003-09-04 Biovail Laboratories Inc. Controlled release dosage forms
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP2033631A3 (en) * 2002-09-03 2009-06-03 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
JP2006503045A (ja) * 2002-09-16 2006-01-26 ワイエス ポリペプチド治療薬剤の経口投与のための遅延放出処方物と同薬剤の使用方法
DK1545475T3 (da) * 2002-10-01 2014-07-28 Banner Pharmacaps Inc Enterisk sammensætning til fremstillingen af blød kapselvæg
WO2004041195A2 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
JP2007517047A (ja) * 2003-12-31 2007-06-28 ジェンザイム・コーポレーション 腸溶コーティングされた脂肪族アミンポリマーの胆汁酸捕捉因子
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
EP1734933B1 (en) * 2004-03-26 2010-05-26 LEK Pharmaceuticals d.d. Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP2803357B1 (en) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
RU2276974C2 (ru) * 2004-07-01 2006-05-27 Некоммерческое партнерство Научно-технический центр "Лекарства и биотехнология" (НТЦ "Лекбиотех") Лекарственное средство "гастропек" для улучшения процессов пищеварения и способ его применения
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
PL1817013T3 (pl) * 2004-11-18 2009-01-30 Bristol Myers Squibb Co Dojelitowa powlekana peletka zawierająca Ixabepilone
WO2006054175A2 (en) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Stable dosage forms of acid labile drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
CN100398122C (zh) * 2005-01-28 2008-07-02 北京北大药业有限公司 一种治疗颈、腰椎病中药的肠溶包衣组合物
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CA2617051C (en) 2005-07-29 2013-12-17 Stichting Groningen Centre For Drug Research Ph-controlled pulsatile delivery system, methods for preparation and use thereof
US8912214B2 (en) * 2005-07-29 2014-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
BRPI0615972A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
SI1919458T1 (sl) 2006-01-27 2012-11-30 Univ California Enterično obloženi cisteamin cistamin in njuniderivati
SI2586435T1 (sl) 2006-03-17 2016-12-30 The Johns Hopkins University Derivati N-hidroksilsulfonamida kot novi fiziološko uporabni donorji nitroksila
WO2008015686A1 (en) * 2006-08-01 2008-02-07 Hetero Drugs Limited Stable multiparticulate formulations of didanosine
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
AU2008304200B2 (en) 2007-09-26 2013-12-19 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
TWI592159B (zh) * 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
RU2498795C2 (ru) * 2007-11-30 2013-11-20 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы лечения неалкогольного стеатогепатита (nash) с применением цистеаминовых продуктов
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
ES2601192T3 (es) 2008-05-07 2017-02-14 Cardioxyl Pharmaceuticals Inc. Nuevos compuestos nitrosos como donadores de nitroxilo y métodos de uso de los mismos
US20090317466A1 (en) * 2008-06-18 2009-12-24 Franco Lori Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine
JP5670325B2 (ja) 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
SG2014014435A (en) * 2009-02-24 2014-07-30 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
TWI463999B (zh) * 2009-03-13 2014-12-11 Toyama Chemical Co Ltd 含有６-氟-３-羥基-２-吡羧醯胺之錠劑及粒狀粉末
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
EP2509942A2 (en) 2009-12-07 2012-10-17 Johns Hopkins University Bis-acylated hydroxylamine derivatives
CA2782110A1 (en) * 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
WO2011137249A1 (en) * 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
AU2011311814B2 (en) 2010-10-08 2016-12-22 Xcovery Holdings, Inc. Substituted pyridazine carboxamide compounds
WO2013049731A1 (en) * 2011-09-30 2013-04-04 Stomavite Llc A supplement for ostomy patients
KR102061537B1 (ko) 2011-10-17 2020-01-03 더 존스 홉킨스 유니버시티 Ｈｎｏ 공여체들로서의 하이드록실아민으로 치환된 멜드럼산, 바르비투르산 및 피라졸론 유도체들
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片
CN102526746B (zh) * 2012-02-04 2013-09-18 安徽山河药用辅料股份有限公司 肠溶型水分散体包衣材料的制备方法
EP2914579A1 (en) 2012-11-01 2015-09-09 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
PT2945620T (pt) 2013-01-18 2018-02-21 Cardioxyl Pharmaceuticals Inc Dadores de nitroxilo com índice terapêutico melhorado
JP6702855B2 (ja) 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド 個別化された新生物ワクチンの組成物及び方法
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN120695169A (zh) 2013-12-20 2025-09-26 博德研究所 使用新抗原疫苗的联合疗法
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US20170216328A1 (en) 2014-04-04 2017-08-03 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
CA2950203C (en) 2014-06-20 2019-09-03 Banner Life Sciences Llc Enteric soft capsule compositions
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
JP2018506514A (ja) 2014-12-23 2018-03-08 セレコー，インコーポレイテッド 化合物、組成物および方法
RU2668499C2 (ru) * 2015-03-12 2018-10-01 Закрытое Акционерное Общество "Фармфирма "Сотекс" Фармацевтическая композиция в форме таблеток, покрытых кишечнорастворимой оболочкой, и способ ее получения
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
CA2986703A1 (en) 2015-06-09 2016-12-15 Rexahn Pharmaceuticals, Inc. Fluorocyclopentenylcytosine uses and processes of preparation
KR20180049015A (ko) 2015-09-04 2018-05-10 렉산 파마슈티컬스, 인코포레이티드 퀴녹살리닐-피페라진아미드의 사용 방법
EP4066846A1 (en) 2015-11-03 2022-10-05 The Brigham & Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
WO2017087532A1 (en) 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
ES2875320T3 (es) 2016-05-04 2021-11-10 Den Driessche Herman Van Formulación de simmondsina
WO2018067422A1 (en) 2016-10-03 2018-04-12 Congxin Liang Novel jak1 selective inhibitors and uses thereof
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
WO2019211492A1 (en) 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
FR3083545A1 (fr) 2018-07-04 2020-01-10 Institut National De La Recherche Agronomique Utilisation d'une souche de roseburia intestinalis pour la prevention et le traitement de l'inflammation de l'intestin
MA53238A (fr) 2018-08-17 2022-04-13 Eidos Therapeutics Inc Formules d'ag10
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US11122828B2 (en) 2018-11-05 2021-09-21 MarvelBiome, Inc. Microbial compositions comprising ellagitannin and methods of use
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020212822A1 (en) * 2019-04-17 2020-10-22 Amruth Gowda Doddaveerappa Multi-component pharmaceutical single dosage forms and process employed thereof
EP3955923A1 (en) 2019-04-18 2022-02-23 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
EP3986163A2 (en) 2019-06-19 2022-04-27 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
CN110882228A (zh) * 2019-11-29 2020-03-17 南京禾瀚医药科技有限公司 一种伊匹乌肽肠溶制剂
CN114786652A (zh) * 2019-12-11 2022-07-22 赢创运营有限公司 用于治疗或预防疾病的剂型
CN116249774A (zh) 2020-05-26 2023-06-09 迪奥尼斯治疗公司 核酸人工微型蛋白质组文库
US20240050415A1 (en) 2020-06-05 2024-02-15 Henry Ford Health System Daclatasvir for use in treating lung and prostate cancer
EP4267554A1 (en) 2020-12-22 2023-11-01 Mekanistic Therapeutics LLC Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
US20240342169A1 (en) 2021-08-10 2024-10-17 Betta Pharmaceuticals Co., Ltd Use of ensartinib or salt thereof in treatment of disease carrying met 14 exon skipping mutation
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2024228542A1 (ko) * 2023-05-04 2024-11-07 풍림무약주식회사 장용성 코팅용 조성물 및 이를 이용한 정제의 제조 방법
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025101914A1 (en) 2023-11-10 2025-05-15 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4432996A (en) 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
GB8512330D0 (en) 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
AU570853B2 (en) 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
PH30058A (en) * 1989-11-24 1996-11-08 Biochemie Gmbh Pancreation preparations
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
WO1992011038A1 (en) * 1990-12-21 1992-07-09 Richardson-Vicks Inc. Polyamine drug-resin complexes
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
SG42869A1 (en) 1992-08-05 1997-10-17 Faulding F H & Co Ltd Pelletised pharmaceutical composition
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції

Also Published As

Publication number Publication date
GEP20032912B (en) 2003-03-25
CO5090840A1 (es) 2001-10-30
AU750388B2 (en) 2002-07-18
JP2002520350A (ja) 2002-07-09
NO20010260D0 (no) 2001-01-16
PL345774A1 (en) 2002-01-02
AU8898398A (en) 2000-02-07
RU2201217C2 (ru) 2003-03-27
EG23944A (en) 2008-01-22
RO121082B1 (ro) 2006-12-29
PT1098635E (pt) 2004-09-30
EE05021B1 (et) 2008-06-16
EE200100033A (et) 2002-06-17
US20020051818A1 (en) 2002-05-02
ES2221188T3 (es) 2004-12-16
AR019934A1 (es) 2002-03-27
CA2337885C (en) 2008-01-08
SK285152B6 (sk) 2006-07-07
IL139701A0 (en) 2002-02-10
BR9815948A (pt) 2001-02-28
KR20010070981A (ko) 2001-07-28
EP1098635A4 (en) 2002-01-16
CA2337885A1 (en) 2000-01-27
ZA993446B (en) 2000-11-20
EP1098635B1 (en) 2004-06-02
DE69824319D1 (de) 2004-07-08
CN1195499C (zh) 2005-04-06
NO20010260L (no) 2001-03-07
LT2001003A (en) 2001-06-25
CZ2001215A3 (cs) 2001-10-17
PL195587B1 (pl) 2007-10-31
HUP0102659A3 (en) 2002-12-28
EP1098635A1 (en) 2001-05-16
BG105203A (bg) 2001-09-28
US6331316B1 (en) 2001-12-18
US6569457B2 (en) 2003-05-27
DK1098635T3 (da) 2004-08-09
TR200003577T2 (tr) 2001-06-21
WO2000003696A1 (en) 2000-01-27
CN1338925A (zh) 2002-03-06
SK18832000A3 (sk) 2002-01-07
LV12638B (lv) 2001-09-20
ATE268165T1 (de) 2004-06-15
NZ508298A (en) 2003-11-28
DE69824319T2 (de) 2005-08-04
UA73092C2 (uk) 2005-06-15
LV12638A (lv) 2001-04-20
NO330554B1 (no) 2011-05-16
LT4844B (lt) 2001-09-25
CZ301557B6 (cs) 2010-04-14
HUP0102659A2 (hu) 2002-03-28
BG65443B1 (bg) 2008-08-29
HU226492B1 (en) 2009-03-02
KR100535954B1 (ko) 2005-12-12

Similar Documents

Publication Publication Date Title
ID27019A (id) Tablet farmasi salutan usus dan metode pembuatan
NO20000932D0 (no) Farmasøytisk preparat for kombinasjon av piperidinoalkanol og dekongestant
NO982809L (no) Prolegemidler av tombin-inhibitorer
ATE300284T1 (de) Ein statin und aspirin enthaltendes arzneimittel
IS5524A (is) Forðatöflur til inntöku
DE69627817D1 (de) Pharmazeutische zubereitung, die fenofibrat und polyglykolisierte glyceride enthält
IS5245A (is) Lyfjablanda úr ómeprasól
PT1189895E (pt) Derivados de tiazole e oxazole e sua utilizacao farmaceutica
PT1221918E (pt) Administracao de drogas sub-tenon
IS5541A (is) Áfangatöflur til inntöku
NO953657D0 (no) Nytt farmasöytisk produkt
NO990944D0 (no) Tablett med kontrollert frigivelse av alfuzosinhydroklorid
KR970012150U (ko) 의약 및 식품용 하드 공 캅셀
ATE263558T1 (de) Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
NO20002831D0 (no) Medikament i myk tablettform og fremgangsmÕter for fremstilling av dette
ID22949A (id) Proses pembuatan tablet hisap flurbiprofen
DK0981334T3 (da) Slugetabletter indeholdende paracetamol
DE59904737D1 (de) Orale arzneiformen mit reproduzierbarer wirkstofffreisetzung von gatifloxacin oder pharmazeutisch verwendbaren salzen oder hydraten
NO20015756D0 (no) Felles promedikamenter av amlodipin og atorvastatin
GB9924334D0 (en) Pharmaceutical products and methods of fabrication therefor
NO983926L (no) Farmas°ytisk kombinasjonspreparat av en inhibitor av natrium-hydrogen-veksler og et legemiddel for behandling av hjertekretsl°p-sykdommer
DE69820861D1 (de) Teilchenförmige arzneimittelträger
IT1289883B1 (it) Composizione farmaceutica antitubercolare e procedimento per la sua produzione
ID23048A (id) Komposisi farmasi protein hedgehog dan penggunaanny a
UA1292S (uk) Таблетка фармацевтична